Enzootic nasal adenocarcinoma (ENA) is a contagious neoplasm of the nasal mucosa of sheep and goats and is associated with enzootic nasal tumour virus (ENTV). As ENA is a common disease in North America and there are no vaccines against ENTV-1, diagnostic tests that can identify infected animals and assist with eradication and disease surveillance efforts are greatly needed. In this study, we endeavoured to develop a novel, non-invasive diagnostic tool that could be used not only to validate clinical signs of ENA but also to detect ENTV-1 infection prior to the onset of disease signs (i.e. pre-clinical diagnosis). Cytology, serology and reverse transcription (RT)-PCR-based diagnostic methods were investigated. Although the cytology-based assay was able to detect ENTV-1 infection in some animals, it had poor sensitivity and specificity and thus was not developed further as an ante-mortem diagnostic method. Three different assays, including ELISA, Western blotting and virus neutralization, were developed to detect the presence of ENTV-1-specific antibodies in sheep serum. Whilst a surprisingly large number of sheep mounted an antibody-mediated immune response against ENTV-1, and in some cases neutralizing, correlation with disease status was poor. In contrast, RT-PCR on RNA extracted from nasal swabs reliably detected exogenous ENTV-1 sequences, did not amplify endogenous ovine betaretroviral sequences, demonstrated high concordance with immunohistochemical staining for ENTV-1 envelope protein, and had perfect sensitivity and specificity. This report describes a practical and highly specific RT-PCR technique for the detection of clinical and pre-clinical ENA that may prove beneficial in future control or eradication programmes.
INTRODUCTION
Enzootic nasal adenocarcinoma (ENA) is an economically important contagious tumour of the nasal mucosa of sheep and goats (De las Heras et al., 2003) . With the exception of Australia and New Zealand, ENA has been recorded worldwide wherever sheep and goats are farmed, with a prevalence of up to 10 % in some areas (De las Heras et al., 2003) . The true economic impact of ENA is not known because affected animals are often culled before actual diagnosis, and suspected disease incidence is rarely reported. Adenocarcinomas of the nasal cavity in sheep have the highest reported prevalence in the USA, Canada, France, Germany and Spain (Caswell & Williams, 2007) . Although the exact prevalence of ENA is unknown, it is not an uncommon disease in North America (Walsh et al., 2010) and is very likely underdiagnosed. Clinical signs of ENA include seromucosal nasal discharge leading to a 'washed nose' appearance, accompanied by snoring, coughing, wheezing and dyspnoea. The duration of disease, from the appearance of clinical signs to the time of death, varies from 3 weeks to 1 year or more. ENA has been transmitted experimentally to goats using concentrated nasal fluid, proving the infectious nature of this disease (De las Heras et al., 1995) . We recently conducted transmission studies in newborn lambs and demonstrated the transmission of ENA using cell-free tumour homogenate (Walsh et al., 2013) .
The retrovirus enzootic nasal tumour virus (ENTV) has been implicated in the aetiology of this lethal and contagious nasal tumour (Cousens et al., 1996 (Cousens et al., , 1999 . Using a mouse mAb against the envelope glycoprotein (Env) of Jaagsiekte sheep retrovirus belonging to the genus Betaretrovirus (Wootton et al., 2006a) , of which ENTV is a member, we were able to verify the presence of the virus in all nasal tumour samples evaluated to date (Walsh et al., tool for diagnostic purposes; however, acquisition of nasal biopsies is costly, and therefore this tool has been restricted to post-mortem use.
Currently, diagnosis of ENA depends on ante-mortem clinical signs and histological findings following postmortem analysis. Serology has not been used for diagnostic purposes, as there is a reported lack of antibody production to the virus capsid in animals with ENA (Ortín et al., 1998) . This lack of immune response is postulated to be due to expression of endogenous ovine betaretrovirus proteins in the thymus and lymphoid tissues during ontogeny (DeMartini et al., 2003; Palmarini et al., 2000) and subsequent elimination of reactive B-cells during negative selection. Additionally, our inability to detect ENTV provirus in PBMCs of either experimentally or naturally infected sheep at any point during the course of infection rules out the use of whole blood for diagnostic purposes (Walsh et al., 2013) . Computed tomography scanning can detect tumours in the nose (Walsh et al., 2013) of ENTVinfected sheep, but this procedure is expensive and is stressful for the animal as it requires transport and anaesthesia. Also, detection of a tumour in these anatomical locations does not conclusively implicate the involvement of ovine betaretroviruses. Therefore, the purpose of this report was to evaluate the utility of reverse transcription (RT)-PCR and IHC analysis of materials obtained from nasal swabs or nasal fluid for diagnosis of ENTV infection in sheep. With this information in hand, it was envisaged that a combination RT-PCR/cytospin assay could be implemented in a test-and-removal programme aimed at eradicating ENTV from sheep flocks.
RESULTS
Pilot study to evaluate the efficacy of a RT-PCRbased assay to detect ENTV-1 in nasal exudates Efforts to develop an ante-mortem diagnostic test were initiated when we received 15 nasal exudate samples from a research flock of Suffolk rams in Quebec, Canada, named QC1 to QC15. All of these rams had, at some point within the last 2 years, displayed clinical signs of ENA, including nasal discharge and noisy breathing. Samples were collected in Trizol LS (2 : 3 ratio of sample to Trizol LS) to preserve RNA. Based on sequence information that we obtained recently from 10 North American ENTV-1 isolates (Walsh et al., 2010) , primers were designed against the U5 and gag regions to specifically detect exogenous ENTV-1 (Fig. 1a) . RNA extracted from healthy sheep lung (negative control) and naturally acquired ENA tissue (positive control) were screened for the presence of ENTV-1 genomic RNA by RT-PCR. In this RT-PCR assay, an ENTV-1-positive sample produced a PCR product of approximately 592 bp (Fig. 1b, lane 15) . No amplification was detected in the negative control (Fig. 1b, lane 17) , confirming the specificity of these primers for exogenous ENTV-1. After confirming the ability of the RT-PCR assay to selectively amplify exogenous ENTV-1 by sequencing of the product from sample QC-12 (data not shown), RNA was extracted from all 15 nasal exudate samples and subjected to cDNA synthesis and RT-PCR for both glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as a control for RNA quality, and ENTV-1 (Table 1) . The RT-PCR results for a subset of animals (QC-1 to QC-6) are shown in Fig. 1(b) . Of the 15 samples submitted for RT-PCR analysis, four were positive for ENTV-1 (Table 1) .
Three RT-PCR-positive and two RT-PCR-negative rams from the putative ENA cluster in Quebec were euthanized and submitted for post-mortem analysis. Upon gross inspection, the three RT-PCR-positive rams had visible tumours, whilst the nasal cavity of the two RT-PCR negative rams looked unremarkable. Tissues harvested from the nasal cavities were subjected to histology and IHC staining with an ENTV-1 Env-specific mAb. ENTV-1 Env expression and histopathological features consistent with ENA were detected in all three RT-PCR/tumour-positive cases (QC-1, QC-12 and QC-15; Table 1 ). For one of the RT-PCR-negative cases (QC-6), a small ENTV-1 Env-positive lesion was identified in the nose by IHC. The other RT-PCR-negative sample appeared normal upon histological and IHC examination (QC-7) (Table 1) . Results from the pilot study revealed a reasonable correlation between RT-PCR positivity and a positive result by IHC for Env protein expression, which is the current gold standard test. Lack of sample availability limited our ability to test the remaining cases by IHC and therefore limited our ability to analyse the specificity and sensitivity of the RT-PCR test on this cohort of animals.
Study to evaluate serology, cytology and RT-PCRbased assays for ante-mortem detection of ENTV-1
Given the promising results of the pilot study, we decided to launch a full-scale study involving a flock of 80 horned Dorset sheep from Ontario with a history of ENA. Additional control samples were obtained from 10 sheep chosen at random from a research flock at the University of Guelph with no history of ENA and which has been closed for 25 years to all new animal additions. In this study, we expanded our sample repertoire to include nasal swabs, cytology samples and serum. Two nasal swabs were collected per animal. One swab was placed in RLT buffer for subsequent RNA extraction and the other was applied to a charged microscope slide for cytological examination.
Gross and histopathological detection of ENA show good correlation with RT-PCR results
Total RNA was extracted from nasal swabs and subjected to RT-PCR as described above. Based on the RT-PCR results (Table 2) , seven ewes that were RT-PCR negative for ENTV-1 infection, 14 ewes that were RT-PCR positive for ENTV-1 infection and one lamb (2013-1) of undetermined status but born to a mother who was RT-PCR positive were submitted for post-mortem analysis. As shown in Fig. 2 , tumours of various sizes, ranging from 0.5 to 8 cm, were detected upon dissection of the nasal cavity. All tumours stained positive for ENTV-1 Env expression by IHC (Table 2, Fig. 3 ), whereas none of the sections from RT-PCRnegative animals were positively stained (Table 2) . Importantly, all of the animals that were RT-PCR-positive for ENTV-1 had tumours, whereas none of the animals that were RT-PCR-negative for ENTV-1 had tumours. No evidence of tumours or Env-positive cells was detected in the lamb born to a mother who was RT-PCR positive for ENTV-1 ( Table 2 ). The specificity and sensitivity of the RT-PCR test were both 100 % (Table 3 ) when the IHC staining for Env protein was used as the gold standard test for calculation purposes. Taken together, these findings suggested that RT-PCR analysis of RNA extracted from nasal swabs represents a sensitive and specific method for detection of ENA.
IHC staining of nasal smears for detection of ENTV-1
To evaluate the use of nasal swab cytology as a method to diagnose ENA, slides from 80 exposed sheep and 10 unexposed controls were stained immunocytochemically for ENTV-1 Env protein and blindly graded by three individuals. Slides were graded as no staining, low-intensity staining, moderate-intensity staining in .10 % of cells or high-intensity staining in ,10 % of cells, and high-intensity staining in .10 % of cells (Fig. 4a-d, respectively) . Isotype-control 3, 5, 7, 9, 11, 13, 15 and 17, RT-PCR products generated using ENTV-1-specific primers (592 bp product); lanes 2, 4, 6, 8, 10, 12, 14, 16 , and 18, RT-PCR products (388 bp product) generated using primers specific for glyceraldehyde 3-phosphate dehydrogenase (GAPDH). RNA isolated from naturally acquired ENA (Pos) and healthy sheep lung (Neg) were used as positive and negative controls, respectively. H 2 O, water-only; M, 1 kb Plus DNA ladder (Life Technologies). Table 1 . RT-PCR and histology results from pilot study staining was performed on a slide from an ENA tumourbearing animal and no staining was observed (data not shown). Although grading results were consistent for some samples (e.g. 2008-1, 2012-12, 2006-37, 2010-44 and 2011-50) , overall there was poor inter-grader agreement (Table 2 ). In addition, the quantity and quality of cells on the slide varied from sample to sample as well as between different regions of the same slide and, in a subset of cases, poor sample representation made grading difficult. Taken together, these results suggested that ENTV-1-infected cells can be identified by immunocytochemical staining of nasal smears but that sample quality would need to be improved to allow appropriate and consistent interpretation. The specificity and sensitivity, which was calculated using IHC as the gold standard, was relatively low compared with the RT-PCR test, at 66.7 and 50 %, respectively (Table 3) . These values were calculated from absolute positive/negative values derived from a consensus of the results from all three graders, and any result with no clear consensus value was not included ( Table 2) .
Detection of ENTV-1-reactive sheep serum by ELISA and Western blot analysis
To investigate whether sheep mount an antibody response to ENTV-1, serum samples were tested for reactivity against recombinant ENTV-1 capsid (ECa) and Env surface subunit (ESU-IgG) proteins using an indirect ELISA ( (2011-36, 2007-28 and 2011-23 ) from group (iv) were positive in both ELISAs. Both ELISA-based tests showed poor agreement with IHC staining for Env protein, as the specificity and sensitivity of the ECa ELISA was 62.5 and 23.1 %, respectively and the ESU-IgG ELISA was 33.3 and 50.0 %, respectively (Table 3) . Thus, the ELISA tests would not be suitable for diagnostic purposes.
Sera from animals submitted for post-mortem analysis were analysed by strip Western blotting to investigate reactivity against denatured ENTV-1 antigens and correlation with ELISA results. Recombinant ECa and ESU-IgG proteins were used as antigens, and polyclonal rabbit anti-ENTV-1 capsid antibody and anti-Env mAb (Wootton Development of an ante-mortem diagnostic test for ENTV-1 et al., 2006a) were used as positive controls, respectively (Fig. 6, lane C) . The majority of serum samples (15/21), including many of those from the control naïve animals (Fig. 6 ), detected a band by Western blot corresponding to ECa ( Table 2 ). Given that there was very little difference in ECa immunoreactivity between serum from exposed and naïve animals, it is likely that serum antibodies were binding non-specifically to ENTV-1 ECa. With a k value of 20.034, agreement between the ECa ELISA and ECa Western blot was poor and was no different from what would be expected by chance alone. Conversely, none of the naïve sheep serum samples detected ESU-IgG in the Western blot (Fig. 6 ). With 6/10 ESU-IgG ELISA-positive samples reacting positively in the Western blot and only 1/ 11 ESU-IgG ELISA-negative samples reacting positively in the Western blot, there was moderate agreement between the ESU-IgG ELISA and the ESU-IgG Western blot (k value of 0.516). Taken together, it would appear that sheep are able to mount an antibody-mediated immune response specifically against exogenous ENTV-1 Env protein.
Serum neutralization of ENTV-1 Env-pseudotyped virions
Heat-inactivated serum samples from animals submitted for post-mortem analysis, and thus with known disease status, were evaluated for their ability to inhibit infection mediated by ENTV-1 Env-pseudotyped murine leukemia virus (MLV) particles. Neutralization was defined as a ¢50 % reduction in infection (as determined by the number of alkaline phosphatase-positive foci) relative to S. R Walsh and otthers untreated virus. Neutralization was observed in 7/13 (53.8 %) samples from the IHC-positive group and 3/8 (37.5 %) samples from the IHC-negative group (Table 2) . Serum from naïve sheep was also tested and no neutralization was observed (data not shown). Despite the fact that the ESU-IgG ELISA and the neutralization assays both detected antibodies specific for the ENTV-1 Env protein, the calculated Cohen's k coefficient was 0.427, demonstrating only moderate agreement between the two tests.
DISCUSSION
ENA is a common disease among North American sheep flocks (Walsh et al., 2010) and, as producer and veterinarian awareness increases, so too does the need for an accurate ante-mortem diagnostic test. Based on our previous findings, PBMCs are not an appropriate source material for detecting ENTV-1, as at no point during the course of infection can ENTV-1 be detected in PBMCs by PCR (Walsh et al., 2013) . In this study, we endeavoured to develop a novel, non-invasive diagnostic tool that could be used not only to confirm clinical signs of ENA but also to detect ENTV-1 infection prior to the onset of disease (i.e. pre-clinical diagnosis). The latter would assist in surveillance programmes and eradication efforts to quarantine and/or eliminate ENTV-1-infected animals from a flock, which would ultimately enhance the health and profitability of the sheep industry. Using clinical samples from a flock with a long history of ENA, we developed and tested serology, cytology and RT-PCR-based assays for utility as diagnostic tools for identification of ENTV-1-infected or ENA-affected sheep. A comparison of RT-PCR, ELISA and cytology results to post-mortem and immunohistological findings showed poor correlation between the presence and absence of Env-positive ENA tumours and results of cytology, ELISA and Western blotting. However, based on small numbers of animals, RT-PCR on RNA extracted from nasal swabs proved to be 100 % sensitive and specific.
As an indication of the sensitivity of this assay, a sheep of less than 8 months of age (2013-7), which was positive by RT-PCR, was found to have a small neoplastic lesion comprised of approximately 50 ENTV-1 Env-positive cells (Fig. 3) .
The RT-PCR assay described in this study has many advantages. In addition to being highly specific for exogenous ENTV-1, it is non-invasive and sample collection is simple to perform. In fact, when we retested nasal swabs that were collected by the producer, we found that the animals had the same RT-PCR status irrespective of who collected the sample (data not shown). As the sampling materials are inexpensive, more than one sample per animal can be collected at one time so as to have a back-up should the RNA extraction fail. By generating cDNA using oligo(dT) and random primers, RNA quality and the presence of ENTV-1 could be assayed from the same cDNA. However, the RT-PCR assay was not amenable to multiplexing, so separate PCRs were required to assess ENTV-1 and GAPDH. This assay could be useful in situations where the veterinarian or producer would like confirmation that clinical signs are in fact due to ENA and not some other condition such as nasal bots or chronic rhinitis. Indeed, one of the sheep (2001-16) in our study had experienced chronic rhinitis and nasal discharge for many months and appeared to be suffering from ENA. This animal was repeatedly negative for ENTV-1 by RT-PCR and upon necropsy it was discovered that the animal had an extensive bacterial infection but no evidence of ENA.
Sheep are thought to be immune tolerant to exogenous ENTV-1 infection. It has been hypothesized that immune cells reactive to endogenous ovine betaretroviruses, which are transcribed in the thymus and peripheral lymph nodes during ontogeny , undergo clonal deletion rendering sheep unable to mount an immune response against invading exogenous ovine betaretroviruses. A study by Ortín et al. (1998) compared serum from healthy sheep to serum from sheep affected by ENA for the presence of antibodies against ENTV-1 capsid fused to glutathione S-transferase (GST). Although some serum samples reacted positively to the antigen, the results were difficult to interpret due to cross-reactivity with the GST protein alone. For this reason, we chose to produce recombinant ENTV-1 capsid protein using a 66His tag bacterial expression system and to remove the His tag prior to using it as an antigen. The results presented here indicate that sheep can respond immunologically to exogenous ENTV-1. Antibodies reactive against both the capsid and the Env protein of ENTV-1 were detected in the serum of sheep from a flock with a high incidence of ENA in both ELISA and Western blot analysis. There was, however, no consistency within ENA-affected and diseasefree groups, such that animals in both groups had immunoreactive antibodies. Moreover, as serum samples from naïve sheep reacted positively with ECa in Western blot analysis, this suggests that the immunoreactivity of serum samples from the flock of sheep with a history of ENA is likely to be non-specific. Conversely, the ESU-IgG ELISA and Western blot analysis detected immunoreactive antibodies in serum samples from the flock with a history of ENA but not in the naïve sheep serum samples, suggesting that these interactions were indeed specific and that sheep are able develop antibodies against the ENTV-1 Env protein.
Results from the virus neutralization assay revealed that the ability of a serum sample to neutralize a virus pseudotyped with the ENTV-1 Env protein did not correlate well with the detection of ENTV-1 Env protein by IHC. The results of the ESU-IgG ELISA and the neutralization assay showed only a moderate correlation (with a Cohen's k value of 0.427), despite the fact that both assays detected antibodies directed against the ENTV-1 Env protein. The ESU-IgG ELISA contains only the ENTV-1 surface subunit whereas the neutralization assay involves the full-length Env (kDa) C M 2°N aive serum 1 Development of an ante-mortem diagnostic test for ENTV-1 protein, including the ectodomain region of the transmembrane subunit. Epitopes in the ectodomain of HIV-1 gp41 (Hessell et al., 2010; Zwick et al., 2001) have been shown to be important targets for broadly neutralizing antibodies, so it is likely that the ELISA-negative neutralizing antibodies in our study represent antibodies targeting the ENTV-1 Env ectodomain. Therefore, the different composition of the antigens used in the two assays could explain this lack of correlation.
Despite the fact that serology cannot reliably be used to diagnose ENTV-1 infection, it is clear that some sheep are able to mount an immune response against the virus. It is likely that the antibodies detected in these experiments represent low-affinity antibodies because high-affinityantibody-producing cells would be deleted in the thymus (Raimondi et al., 2007) . Low-affinity-antibody-producing cells, on the other hand, could escape clonal deletion and be induced to expand when exposed to exogenous ENTV-1 antigens on antigen-presenting cells in the periphery. We do not, however, know whether disease-free sheep that mounted an immune response against ENTV-1 were at one point infected with the virus and controlled the infection. Nevertheless, it is possible that the immune system may be a factor in determining the outcome of ENTV-1 infection, particularly in animals where tolerance to ENTV-1 is broken and neutralizing antibodies are developed. Lastly, animals confirmed to have ENA by IHC and that lack neutralizing antibodies could shed ENTV-1 chronically and potentially infect a significant proportion of the flock.
Given that ENTV-1-infected sheep can harbour infectious tumours and exist in a flock unnoticed for a considerable amount of time, or be sold as healthy animals, there is an urgent need for a rapid and reliable ante-mortem diagnostic test for ENA for use in individual sheep. This report describes a practical and highly specific RT-PCR technique for the detection of clinical and pre-clinical ENA that may prove beneficial in future control or eradication programmes.
METHODS
Sample collection. All work with animals was conducted in strict accordance with the Canadian Council of Animal Care guidelines. The animal use protocol was approved by the Animal Care Committee of the University of Guelph. All efforts were made to minimize suffering. Two groups of sheep were sampled. The first group consisted of 15 Suffolk rams from a research flock in Quebec, Canada, that had displayed clinical signs of ENA, including nasal discharge and noisy breathing, on and off for more than 2 years. Approximately 0.5 ml nasal exudate was combined with 0.75 ml of the RNA preservative Trizol LS (Life Technologies; 2 : 3 ratio), transported on ice and stored at 280 uC. RNA was extracted according to the manufacturer's instructions and stored at 280 uC until cDNA synthesis was performed. The second group of animals enrolled in the study consisted of 80 horned Dorset sheep aged 6 months to 16 years belonging to a commercial flock with a long history of ENA. In this group, both nostrils were sampled by gently rubbing the nasal turbinates with an 8-inch sterile cytobrush (Fisher Scientific). Two nasal swabs were obtained per animal. The first swab was transferred to a charged microscope slide (Superfrost Plus; Fisher Scientific) using standard procedures and transported to the laboratory immersed in PBS. Once in the laboratory, the slides were fixed in 4 % paraformaldehyde for 10 min and stored in PBS at 4 uC until immunocytochemical staining was performed. For the second swab, the tip of the cytobrush was cut off and placed into a 1.5 ml microfuge tube containing 0.5 ml RLT buffer (Qiagen). Specimens were transported to the laboratory on ice and frozen at 280 uC within 4 h of collection. Blood samples were obtained by venipucture of the jugular vein using serum-separating vacutainer tubes (Becton Dickinson). A subset of animals was submitted for post-mortem analysis and nasal tissue was harvested for formalin fixation.
IHC and immunocytochemical staining. Fixed tissues were embedded in paraffin, sectioned at 5 mm and stained with haematoxylin and eosin. The avidin-biotin-peroxidase complex method was used on paraffin-embedded tissue sections for IHC demonstration of ENTV Env protein expression, as described previously (Walsh et al., 2013) . Immunocytochemical staining of nasal smears was conducted as above except that deparaffinization and hydration steps were excluded. For the nasal smears, three randomly selected fields per slide were evaluated by three independent graders.
Production of ENTV-1 capsid antibody. The ENTV-1 capsid gene was amplified from ENA tumour tissue using forward (ECaF, 59-GCTAGCCCTGTTTTTGAAAATAATAACCAG-39) and reverse (ECaR 59-GAATTCTTAAGCAATACCTTGCATGTAGTA-39) primers, which contain an NdeI and an EcoRI restriction site, respectively. The capsid amplicon was cloned into the pET28a plasmid (Novagen) using restriction sites included in the primers to produce pET28aECa, which contains an N-terminal 66His tag fused to the ENTV-1 capsid protein by a thrombin cleavage site. Capsid protein was expressed and purified in BL21 Star Escherichia coli cells using IPTG induction and a Ni-NTA Fast Start kit according to the manufacturer's instructions (Qiagen). Eluted protein was processed with a Thrombin CleanCleave kit according to the manufacturer's instructions (Sigma) and a nickel column was used to remove the His tag. Purified capsid protein lacking the His tag was sent to Pacific Immunology for generation of rabbit hyperimmune serum. The resultant polyclonal antibody was able to efficiently detect both ENTV and JSRV capsid protein at a dilution of 1 : 10 000.
ELISA. Serum antibodies reactive with ENTV-1 capsid and Env proteins were detected by indirect ELISA. Recombinant antigens used in the ELISA were prepared as follows. Recombinant capsid protein from ENTV-1 (ECa) was expressed in E. coli using the pET28a System (Novagen) and purified using a nickel column as described above. ESU-IgG, a fusion protein comprising the surface subunit of the ENTV-1 Env protein fused to the Fc domain of human IgG1 (Van Hoeven & Miller, 2005) , was purified from the supernatant of 293T cells transfected with pCMV-ESU-IgG using a HiTrap protein GSepharose column (GE Healthcare) according to the manufacturer's instructions. Briefly, flat-bottomed 96-well plates (VWR International) were coated with 200 ng purified ECa (2 mg ml
21
) or ESU-IgG (2 mg ml 21 ) per well and incubated at 4 uC overnight. The plates were then washed with PBS plus 0.5 % Tween 20 and blocked for 1 h at room temperature with PBS containing 5 % non-fat dried milk. Serum samples were diluted in blocking buffer and added to the 96-well plates. The plates were then incubated at room temperature for 2 h. Following three washes in PBS/0.5 % Tween 20, HRP-conjugated rabbit antisheep IgG (Life Technologies) (diluted 1 : 10 000 in blocking buffer) was added and the plates were incubated for 1 h at room temperature. The plates were washed and the reaction was visualized by the addition of 100 ml ABTS substrate (Mandel Scientific) for 10 min. Absorbance was measured at 405 nm using a microplate reader (Bio-Tek Instruments). Rabbit polyclonal antibody raised against bacterially expressed ENTV-1 capsid protein (ECa) (described above) and a mouse mAb that cross-reacts with the ENTV Env protein (Wootton et al., 2006b) were used as positive controls with the appropriate HRPconjugated secondary antibodies.
Immunoblot analysis. ECa and ESU-IgG proteins resolved by 15 % SDS-PAGE were transferred to PVDF membrane and blocked overnight at 4 uC in PBS/0.5 % Tween 20 containing 5 % non-fat dried milk. The membrane was then cut into evenly sized strips and probed with individual sheep serum samples (diluted 1 : 50 in blocking buffer) at 4 uC for 16 h. The strips were washed with PBS/0.5 %Tween 20 and incubated with a 1 : 5000 dilution of HRP-conjugated rabbit anti-sheep IgG (Life Technologies) in blocking buffer for 1 h at room temperature. The membrane strips were developed using Western Lightning Plus ECL (PerkinElmer) and imaged with a ChemiDoc XRS (Bio-Rad).
Virus neutralization assay. The ability of serum samples to neutralize ENTV-1 Env-mediated infection was assessed by a neutralization assay. Briefly, NIH 3T3/LL2SN cells (Rai et al., 2001) , which overexpress the receptor for ENTV-1, Hyal2, were seeded in 12-well plates at 1610 5 cells per well. After 16 h, the sheep serum samples were heat inactivated at 56 uC for 30 min, mixed at a 1 : 50 dilution with~400 infectious ENTV-1 Env-pseudotyped MLV particles expressing human placental alkaline phosphatase (AP) in a total volume of 500 ml and incubated for 30 min at 37 uC. Note that the MLV particles were produced in LGPS/LAPSN cells [NIH 3T3 cells that express Moloney murine leukemia virus Gag and Pol (Miller et al., 1991) and contain the LAPSN retroviral vector, which expresses a human placental AP gene (Miller et al., 1994) ] transfected with pSX2EenvI4, a plasmid expressing a modified version of the ENTV-1 Env protein with enhanced pseudotyping efficiency (S. R. Walsh, personal communication), as described previously (Wolgamot et al., 1998) . The virus/serum mixtures were then added to NIH 3T3/LL2SN cells in the presence of 8 mg polybrene ml 21 and incubated for 4 h before replacing with 1 ml fresh medium. The cells were fixed 48 h later with 3.7 % formaldehyde and stained for AP activity as described previously (Van Hoeven & Miller, 2005) . The assay was performed in quadruplicate, and neutralization was defined as a ¢50 % reduction in AP-positive foci compared with PBS-treated samples.
RNA extraction and RT-PCR. Total RNA was extracted from nasal exudate stored in Trizol LS according to the manufacturer's instructions. Total RNA was extracted from the nasal swabs stored in RLT buffer using an RNeasy kit (Qiagen). cDNA libraries were synthesized using qScript Flex cDNA SuperMix (Quanta Biosciences) and a combination of random and oligo(dT) primers. A fragment of the 59 end of the ENTV genome was amplified (Fig. 1) using Platinum PCR SuperMix (Life Technologies) and the ENTV-U5-F (59-GATG-CTCCGTTCTCTCCTTATA-39) and GAG-R (59-GGGACGCGAC-GAATGTAGG-39) primer pair (Walsh et al., 2010) . The efficiency of RNA extraction and cDNA generation was tested using forward (59-TGTTCCAGTATGATTCCACCC-39) and reverse (59-ATAAGTCC-CTCCACGATGCC-39) primers specific for exons 3 and 6, respectively, of ovine GAPDH (Philbey et al., 2006) . Selected RT-PCR products were sequenced to verify the identity of the amplicons.
Statistical analysis. Sensitivity, specificity and k coefficient analysis was performed using GraphPad Prism v.6 software. Specificity and sensitivity was calculated using the results of the anti-Env IHC staining of nasal tissue as the gold standard. Calculations included only the results from the 22 animals from the 80 horned Dorset flock for which post-mortem tissue samples were available.
